| Name | CSF1R-IN-2 |
| Description | CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively). |
| In vitro | The suppression of MET autophosphorylation as well as the downstream STAT3 caused by CSF1R-IN-2, ERK and AKT phosphorylation at IC50 values of around 1-3 nM in SNU-5 and MKN-45 cell lines. |
| In vivo | In mice, CSF1R-IN-2 (p.o., BID, 13 days) treatment results in an 85% tumor regression, and no bodyweight loss is observed after 21 days of treatment. In SCID/Beige mice. CSF1R-IN-2 (p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID, and 15 mg/kg, BID, respectively. In mice, CSF1R-IN-2 inhibits MET activity in MKN-45 tumors following oral administration. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (61.06 mM), Sonication is recommended.
|
| Keywords | CSF1R-IN-2 | colony stimulating factor 1 receptor | CSF-1R | CSF1R IN 2 | inhibit | CSF1RIN2 | c-Met/HGFR | CSF1R | CSF-1R-IN-2 | Inhibitor | CSF-1 receptor | Src | c-Fms |
| Inhibitors Related | Nintedanib | PLX5622 | Vemurafenib | Staurosporine | Sotuletinib | L-Ascorbic acid 2-phosphate trisodium | Pazopanib Hydrochloride | Pexidartinib | Ibrutinib | Dasatinib | Crizotinib | Ponatinib |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Liver Cancer Compound Library |
United States
